Población no seleccionada por met hepáticas
15/02/2017
•
Rate of surgical resection
–
18 patients (13%) in the panitumumab arm
–
16 patients (11%) in the bevacizumab arm
•
R0 resection was reported for
–
14 patients (10%) in the panitumumab arm
–
12 patients (8%) in the bevacizumab arm
PEAK
Panitumumab
+ mFOLFOX6
ETS < 20%
ETS ≥ 20%
n (%)
20 (25)
60 (75)
Median PFS, months (95%
CI)
9.8
(4.2
‒
15.4)
13.1 (10.9
‒
16.2)
HR (95% CI)
0.46 (0.25
‒
0.86)
Median OS, mo ths (95%
CI)
21.2 (14.1
‒
41.2)
43.4
(36.4
‒
55.4)
HR (95% CI)
0.38 (0.20
‒
0.69)
